For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Lineage Cell Therapeutics Inc’s stock clocked out at $1.82, up 1.11% from its previous closing price of $1.8. In other words, the price has increased by $1.11 from its previous closing price. On the day, 0.99 million shares were traded. LCTX stock price reached its highest trading level at $1.85 during the session, while it also had its lowest trading level at $1.78.
Ratios:
To gain a deeper understanding of LCTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.08 and its Current Ratio is at 4.08. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 24 ’25 when DON M BAILEY bought 60,000 shares for $1.60 per share.
DON M BAILEY bought 80,000 shares of LCTX for $97,472 on Sep 10 ’25. On Jan 27 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the Director of the company, bought 7,894,737 shares for $0.76 each. As a result, the insider paid 6,000,000 and bolstered with 49,560,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 415608448 and an Enterprise Value of 374201440. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.09 while its Price-to-Book (P/B) ratio in mrq is 8.59. Its current Enterprise Value per Revenue stands at 34.286 whereas that against EBITDA is -18.93.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.78, which has changed by 0.978022 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $2.09, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 15.58%, while the 200-Day Moving Average is calculated to be 95.65%.
Shares Statistics:
It appears that LCTX traded 1.71M shares on average per day over the past three months and 2201930 shares per day over the past ten days. A total of 228.36M shares are outstanding, with a floating share count of 215.49M. Insiders hold about 5.63% of the company’s shares, while institutions hold 43.05% stake in the company. Shares short for LCTX as of 1760486400 were 31772044 with a Short Ratio of 18.54, compared to 1757894400 on 27748083. Therefore, it implies a Short% of Shares Outstanding of 31772044 and a Short% of Float of 24.83.
Earnings Estimates
The firm’s stock currently is rated by 6.0 analysts. The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.16 and -$0.21 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.08, with 6.0 analysts recommending between -$0.04 and -$0.13.
Revenue Estimates
In. The current quarter, 7 analysts expect revenue to total $2.3M. It ranges from a high estimate of $3.3M to a low estimate of $1.35M. As of. The current estimate, Lineage Cell Therapeutics Inc’s year-ago sales were $3.78MFor the next quarter, 7 analysts are estimating revenue of $2.08M. There is a high estimate of $3.4M for the next quarter, whereas the lowest estimate is $383k.
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $10.8M, while the lowest revenue estimate was $6.2M, resulting in an average revenue estimate of $8.63M. In the same quarter a year ago, actual revenue was $9.5M
